SCHEMBL25520137

SCHEMBL25520137

CC(C)OC(=O)NC1C2CN(c3nccs3)CC21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.44
DPP8 Q6V1X1 1/20 0.44
DPP9 Q86TI2 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4C Q9H3R0 1/20 0.37
GRM5 P41594 1/20 0.37
GRM1 Q13255 1/20 0.37
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
GLA P06280 1/20 0.36
HPGDS O60760 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CHRNA7 P36544 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25520140 0.82 DPP4 (0.44) DPP4DPP8DPP9DPP7HRH3
SCHEMBL25520138 0.79 HDAC3 (0.33) HRH3
SCHEMBL25519339 0.72 HTT (0.36) HRH3HTTALDH1A1GLANPC1
SCHEMBL972766 0.71 HPGD (0.45) HPGDHTTHSD17B10KDM4C
SCHEMBL25519169 0.68 MEN1 (0.39) HPGDHTTALDH1A1GRM5GLA
SCHEMBL21122285 0.68 MEN1 (0.39) HPGDHTTALDH1A1GRM5GLA
SCHEMBL25520144 0.68 HRH3 (0.56) HRH3HPGDHTTHSD17B10GRM5
SCHEMBL4636614 0.67 NPC1 (0.40) DPP4DPP8DPP9DPP7HPGD
SCHEMBL19080603 0.67 HPGD (0.44) DPP4DPP8DPP9DPP7HRH3
SCHEMBL2640732 0.66 KDM4C (0.44) DPP4DPP8DPP9DPP7HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed
EP-4108663-A1 SUBSTITUTED ARYL COMPOUND Simcere Pharmaceutical Co., Ltd. (CN) 2022-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM DPP4 4394/4885DPP8 3557/4885DPP9 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.